Your email has been successfully added to our mailing list.

×
0 0 0.0259202453987729 0.0122699386503068 0.0154601226993864 -0.00306748466257676 -0.0398773006134969 -0.0521472392638037
Stock impact report

Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha]

Kazia Therapeutics Limited - American Depositary Shares (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com
Company Research Source: Seeking Alpha
Ultra-thinly traded nano cap Kazia Therapeutics (NASDAQ:KZIA18%interim dataPhase 2 clinical trialAt data cutoff, median overall survival was 17.7 months compared to 12.7 months associated with current standard-of-care temozolomide (chemo drug).Median progression-free survival also favored paxalisib, 8.5 months vs. 5.3 months.The company expects to announce additional interim data in H3 and final results in H1 2021, adding that four other studies are underway assessing Show less Read more
Impact Snapshot
Event Time:
KZIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for KZIA alerts
Opt-in for
KZIA alerts

from News Quantified
Opt-in for
KZIA alerts

from News Quantified